China Tracker - Details for 3SBio Inc. (SSRX)


Warning: fopen(http://finance.yahoo.com/d/quotes.csv?s=SSRX&f=snl1a2xf6): failed to open stream: HTTP request failed! HTTP/1.0 403 Forbidden in /home/fixyou/public_html/tracker_details.php on line 58

Warning: fgetcsv() expects parameter 1 to be resource, boolean given in /home/fixyou/public_html/tracker_details.php on line 60

Warning: fclose() expects parameter 1 to be resource, boolean given in /home/fixyou/public_html/tracker_details.php on line 61
 3SBio Inc.
 Analyst Coverage
2011-08-18Capstone InvestmentsDowngradeHoldn/a
2011-08-16HSBCReiterationOverweight$21.20
2011-07-12HSBCReiterationOverweight$21.20
2011-06-17Capstone InvestmentsReiterationBuy$24.00
2011-05-16Capstone InvestmentsReiterationBuy$24.00
2011-05-12Piper JaffrayReiterationOverweight$22.00
2011-04-28OppenheimerInitiationOutperform$21.00
2011-03-16Morgan StanleyReiterationOverweightn/a
2011-03-16Piper JaffrayReiterationOverweight$22.00
2011-01-31OppenheimerReiterationOutperform$17.50
2011-01-11OppenheimerReiterationOutperformn/a
2010-12-07Piper JaffrayReiterationOverweight$18.00
2010-12-02Piper JaffrayReiterationOverweight$18.00
2010-11-17Piper JaffrayReiterationOverweight$18.00
2010-10-10Global HunterDowngradeDroppedn/a
 

We are discontinuing coverage of the company due to the departure of our analyst

2010-08-18Piper JaffrayReiterationOverweight$16.00
2010-07-02Global HunterInitiationBuy$15.00
 

We are initiating coverage of 3SBio Inc. (SSRX) with a Buy rating and a 12- to 18-month price target of $15.00. SSRX is our top small-cap pick in the China healthcare space, predicated on the following: 1) substantial and growing leadership position in China's EPO market; 2) significant opportunity in nephrology; 3) solid organic sales growth on current products; 4) pipeline products are synergistic to SSRX' current market focus; and 5) conservative management and cash deployment. Moreover, we view SSRX' risk profile as relatively limited based on each individual risk’s low probability of occurrence. Our 12- to 18-month PT of $15 implies a P/E multiple of 19x our 2011E EPS of $0.75.

SSRX
Healthcare & Drugs
SCORE
2
READ: Score Cards Explained
SAFETY/RISK SCORE
HIGH SAFETY
DETAILS: Safety/Risk Model for SSRX
Current Price:  n/a
F10k Day (2007-02-07): -100.00%$14.85
2009 Close: -100.00%$13.69
2010 Close: -100.00%$15.18
2011 Close: -100.00%$10.22
High (2012-10-16): -100.00%$14.25
Low (2012-07-31): -100.00%$10.15
Exchange:
Market Capitalization: n/a
Total Shares: 22.42 mill
Float: n/a
Avg Volume: 71.70 k
Short Interest: 127.20 k
Short Ratio: 0.97%1.8 d
Last Quarter: 2011-03-31
Revenue (MRQ): 18.06 mill
Net Income (MRQ): 3.39 mill
all financial data provided without warranty